Our experienced team as veterans in the biotechnology industry, identifies various investment opportunities in botanic new drugs, chemical drugs, protein drugs, glycosylation drugs, cell therapy, advanced med-tech. We assist and guide entrepreneurs in translating promising technology with market potential from the laboratory to global markets.
Building Flagship Biotech Companies
In addition to providing funds and serving on boards, we offer abundant resources to help new startups establish systems related to R&D, finance, IT, auditing, legal, and corporate governance. We actively provide operational and strategic advice and execution, enabling management teams to concentrate on accelerating key technology and product development, ultimately creating flagship biotech companies.
Investing in Future Leaders
Talents and teams are at the core of our investments. We are dedicated to identifying top scientists in respective research fields and co-founding early-stage companies with exceptional entrepreneurial teams. We provide continuous support to create both product and investment value.
Creating Explosive Investment Value
We are committed to generate optimal shareholder returns within our investment portfolio. Through precise risk management and efficient demonstration of portfolio market value, we strategically access the capital market at the right time. While we continuously help maintain the value of individual portfolio companies, we exit strategically and quietly to optimize investment returns.
The 7 Major Investment Focuses
Innovative technologies, platforms, and business models with worldclass competitiveness
First-in-class or best-in-class novel drugs addressing unmet medical needs
High-end and market-oriented medical devices with high levels of innovation
Advanced drugs optimizing cancer treatment outcomes through immune modulation checkpoints
Key technologies and therapeutic drugs related to nucleic acid target delivery
New drugs, medical devices, or medical foods related to microbiome, specific strains, and their metabolic products
Collaboration or mergers involving the aforementioned technologies, products, and enterprises
